Skip to main content

Table 3 High cost noted in the CDR reimbursement recommendation statements for drugs for disorders with a prevalence of ≤10 per 100,000, by time period

From: Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost

Time period

Recommendation

Prevalence of treated disorder (per 100,000)

Total

  

≤10 to >1

≤1

 

Before 2012

Positive

1 (20.0%)

0 (0.0%)

1 (14.3%)

Negative

6 (85.7%)

5 (83.3%)

11 (84.6%)

2012 onward

Positive

8 (100.0%)

1 (100.0%)

9 (100.0%)

Negative

0 (0.0%)

0 (0.0%)

0 (0.0%)

  1. CDR Common Drug Review